Boston Scientific's WATCHMAN FLX Shows Superior Bleeding Risk Reduction in 3-Year Study
Stock Titan Boston Scientific announced positive three-year results from the OPTION clinical trial of its WATCHMAN FLX™ Left Atrial Appendage Closure Device …
Read the original at stocktitan.net ↗
- Topics
- Markets & InvestmentHealthcare
- Tags
- AI Use Case
- Tracked via
- Google Alert “AI Risks”